Arterioscler Thromb Vasc Biol (1990), 10:198-207 Di Pasquale G, Ribani M, Andreoli A, Angelo Zampa G, Pinelli G
MDMA (ecstasy) pharmacokinetics in a CYP2D6 poor metaboliser and in nine CYP2D6 extensive metabolisers
Phenomix CEO Mark Bagnall discusses the reasons for GLP-1 failure and why its common for patients to stop taking the medication
There is no prize for suffering through the day without food
But inadequate protein intake during rapid weight loss leads to muscle loss, metabolic rate reduction, and worse long-term outcomes
Reasons to revisit your dosing plan include: Plateau in weight loss Persistent side effects Changes in lifestyle or health status Transitioning between medications or brands Always make adjustments under the supervision of a medical professional